Brexanolone Injection (Zulresso)

Covered: Zulresso (brexanolone) is covered only for FDA‑approved moderate to severe postpartum depression in adults within ≤6 months postpartum (not for mild depression, pregnant patients, or those <18 years), limited to a one‑time 60‑hour IV infusion (up to 90 mcg/kg/hr) per postpartum period. Key requirements: must be prescribed by or in consultation with a psychiatrist or obstetrician‑gynecologist and documented with diagnosis/severity, date of delivery (≤6 months), pregnancy status, patient age, dosing/treatment plan (one‑time 60‑hr infusion), and REMS/safety program compliance.

"Treatment of postpartum depression (PPD) in adults (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.